Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 261Neoplasms 143Breast Neoplasms 140Colorectal Neoplasms 124Prostatic Neoplasms 94Neoplasm Metastasis 93Multiple Myeloma 92Ovarian Neoplasms 91Lung Neoplasms 86Squamous Cell Carcinoma of Head and Neck 62Pancreatic Neoplasms 62Recurrence 59Endometrial Neoplasms 55Melanoma 52Small Cell Lung Carcinoma 51Leukemia, Lymphocytic, Chronic, B-Cell 48Stomach Neoplasms 47Carcinoma, Renal Cell 46Leukemia, Myeloid, Acute 44Lymphoma, Non-Hodgkin 40Advanced Solid Tumors 39Urinary Bladder Neoplasms 37Triple Negative Breast Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 36Lymphoma, Large B-Cell, Diffuse 36Head and Neck Neoplasms 36Carcinoma, Hepatocellular 35Lymphoma, Follicular 30Esophageal Neoplasms 30Myasthenia Gravis 27

Interventions

pembrolizumab 1cemiplimab 1Pemetrexed 1Cisplatin 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-small Cell Lung Cancer × 30 days × Clear all
NCT05420220 2026-05-28

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Completed
95 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06452277 2026-05-18

SOHO-02

Bayer

Phase 3 Recruiting
444 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Regeneron Pharmaceuticals

Active not recruiting
1,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡